Medications

ASH: Daratumumab beneficial for patients with multiple myeloma

For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with ...

page 1 from 6